Share on LinkedInShare on LinkedIn

ARTICLE · 21 JULY 2022

Janssen Succeeds On Infringement Against Apotex In Macitentan Combination Patent Case

In a public decision dated July 6, 2022 in an action under the Patented Medicines (Notice of Compliance) Regulations, Justice Pallotta of the Federal Court found that Apotex...

CanadaIntellectual Property

In a public decision dated July 6, 2022 in an action under the Patented Medicines (Notice of Compliance) Regulations, Justice Pallotta of the Federal Court found that Apotex would infringe Janssen's patent relating to Janssen's OPSUMIT (macitentan) by selling APO-MACITENTAN: Janssen Inc v Apotex Inc, 2022 FC 996. Apotex did not challenge validity.

Canadian Patent No. 2,659,770 (770 Patent) was the subject of an earlier s. 6(1) action involving Janssen and Sandoz, in which the Court rejected Sandoz's validity attacks. The 770 Patent relates to macitentan in combination with a phosphodiesterase type-5 inhibitor (PDE5-I) (for example, sildenafil) to treat diseases where vasoconstriction is involved, including pulmonary arterial hypertension (PAH).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

See more popular content from